Century Therapeutics, Inc. has made a significant announcement regarding its iPSC-derived cell therapy, CNTY-813. The company presented nonclinical data at the European Association for the Study of Diabetes (EASD) conference held in Milan, Italy, on October 2, 2026. This development is crucial as it indicates progress toward clinical trials for a therapy aimed at treating type 1 diabetes.

Century Therapeutics, based in Philadelphia, Pennsylvania, focuses on developing induced pluripotent stem cell (iPSC)-derived therapies. The company operates under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products (no diagnostic substances). Century trades on the Nasdaq under the ticker IPSC and is classified as an emerging growth company.

The latest filing reveals that the data presented at EASD demonstrates CNTY-813's capabilities in maintaining glycemic control in a diabetic mouse model. Brent Pfeiffenberger, Chief Executive Officer of Century Therapeutics, stated, "The data presented at EASD build on the nonclinical package we presented at ADA in June and highlight our continued execution on bringing CNTY-813 into the clinic." He further noted that the company is on track to submit the Investigational New Drug (IND) application for CNTY-813 in the fourth quarter of 2026, with initial clinical data expected in the second half of 2027.

Key findings from the EASD presentation included:

  • Glycemic control sustained until graft removal in diabetic mice, demonstrating the pharmacological activity of CNTY-813.
  • Successful engraftment of CNTY-813 in the liver of rats, supporting the planned clinical route of administration.
  • Consistent product profiles across five clinical-scale batches produced during the Phase 1 manufacturing process.

These results not only bolster Century Therapeutics' position in the biotechnology industry but also highlight the competitive landscape for companies developing therapies for diabetes. The advancements in CNTY-813 may prompt competitors in the biological products sector to accelerate their own research and development efforts.

As for what’s next, Century Therapeutics has indicated that it will proceed with the IND submission for CNTY-813 as planned. The filing does not specify any additional steps beyond the IND submission, but the anticipation of clinical data in 2027 sets a clear timeline for stakeholders.